Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy.
Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute5150 Centre Avenue, 5th Floor, Pittsburgh, Pennsylvania, 15232USADivision of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Molecular Genomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSA.
Jessica L
JL
Geiger
Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute5150 Centre Avenue, 5th Floor, Pittsburgh, Pennsylvania, 15232USADivision of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Molecular Genomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSA.
Simion I
SI
Chiosea
Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute5150 Centre Avenue, 5th Floor, Pittsburgh, Pennsylvania, 15232USADivision of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Molecular Genomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSA.
Sue M
SM
Challinor
Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute5150 Centre Avenue, 5th Floor, Pittsburgh, Pennsylvania, 15232USADivision of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Molecular Genomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSA.
Marina N
MN
Nikiforova
Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute5150 Centre Avenue, 5th Floor, Pittsburgh, Pennsylvania, 15232USADivision of Anatomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSADivision of Molecular Genomic Pathology, Department of Pathology, University of Pittsburgh Medical CenterPittsburgh, PennsylvaniaUSA baumanje@upmc.edu.
Julie E
JE
Bauman
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D058990:Molecular Targeted Therapy; D018814:Multiple Endocrine Neoplasia Type 2b / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation / Q000235:genetics*; D051096:Proto-Oncogene Proteins c-ret / Q000037:antagonists & inhibitors* / Q000235:genetics*; D012074:Remission Induction
D051096:Proto-Oncogene Proteins c-ret